Press

Acarix presents at the Redeye event, Theme: Diagnostics

22 Sep

On September 27 at 11.30 am CEST, Helen Ljungdahl Round, President and CEO at Acarix will present the company´s latest developments within Diagnostics.

The presentation will be live broadcast at this link:
 https://www.redeye.se/events/846227/redeye-theme-diagnostics

The recording and the presentations will also be available after the event at https://www.acarix.com/news/news

For more information contact:
Helen Ljungdahl Round, CEO, phone +1 267 809 1225, +46 730 770283, email [email protected] 
Christian Lindholm, CFO, phone +46 705 118333, email [email protected]

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor®System uses advanced acoustics and AI-technology to rule out CAD non-invasively in less than 10 minutes, with at least 96% certainty. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, [email protected]) is Certified Advisor of Acarix. For more information, please visit www.acarix.com. 

Attachments
Acarix presents at the Redeye event, Theme: Diagnostics

Tags:
,
Newer Acarix and the American College of Cardiology announce strategic collaboration
Back to list
Older Helen Ljungdahl Round, President and CEO presents at Redeye event, Theme: Diagnostics

Related Posts